Data Requirements for Patenting Biotech/Pharma Inventions in China and the EU

In Webinars

1 July, 2020

This interactive webinar considers the filing and post-filing data requirements for biotechnology and pharmaceutical-related inventions in China and the EU. Xiaofan Chen, Hai Liu and Helle Friis Svenstrup from AWA’s Asian and European offices explain the minimum data requirements during filing and also the criteria for supplementary data. They also consider the use of post-grant data as evidence during invalidation proceedings. Understanding the differences between the European and Chinese regimes is essential for applicants to be successful.

 

 

 

You may also be interested in:

Swissness

Swissness – recent developments in protecting the “Swiss” brand

It is no secret that Swiss products and services enjoy a great reputation both at home and abroad. They

Read more...

Beijing IP Court awards Shell statutory damages

In a recent base before the Beijing IP Court, oil and gas giant Shell International received the maximum amount

Read more...

China amends Guidelines for Patent Examination

In response to the latest PRC Patent Law, the CNIPA has revised the Guidelines for Patent Examination. Hai Liu

Read more...

Mobile Sliding Menu